Dr Mary Kerr, CEO of KaNDy Therapeutics to present at the 25th Annual BIO-Europe Conference During the BIO-Europe conference taking place from [...]
Developing a breakthrough non-hormonal treatment for multiple symptoms of the menopause including hot flashes and night time awakening
A unique approach
Progressing our unique once daily dual mechanism neurokinin antagonist, NT-814, as a potential breakthrough treatment for multiple symptoms of the menopause. NT-814 has successfully completed a Phase 2a proof of concept study that demonstrated its potential to rapidly and profoundly reduce two key symptoms of the menopause: hot flashes and night time awakening.
The Phase 2b study, named SWITCH-1, to evaluate the effect of treatment with NT-814 on hot flashes and other symptoms of the menopause was initiated in December 2018. Results from the SWITCH-1 study are expected in late 2019.
For general, media or partnership enquiries, get in touch with us: